Systemic in vivo lentiviral delivery of miR-15a/16 reduces malignancy in the NZB de novo mouse model of chronic lymphocytic leukemia

Genes and Immunity

Volumn 13, Issue 2, 2012, Pages 109-119

  Kasar, S ^a   Salerno, E ^a   Yuan, Y ^a   Underbayev, C ^a   Vollenweider, D ^a   Laurindo, M F ^a   Fernandes, H ^a   Bonci, D ^b   Addario, A ^b   Mazzella, F ^a   Raveche, E ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

chronic lymphocytic leukemia; lentivirus; microRNA; mouse models

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GREEN FLUORESCENT PROTEIN; LENTIVIRUS VECTOR; MICRORNA; MICRORNA 15A; MICRORNA 16; UNCLASSIFIED DRUG;

AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CANCER MODEL; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TARGETING; FLOW CYTOMETRY; GENE EXPRESSION; GENOMIC INSTABILITY; GROUPS BY AGE; HISTOPATHOLOGY; IN VIVO GENE TRANSFER; LEUKEMIA CELL; LIVER FUNCTION; MOUSE; NEW ZEALAND BLACK MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; DISEASE MODELS, ANIMAL; GENE THERAPY; LENTIVIRUS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICE; MICRORNAS;

LENTIVIRUS; MUS;

EID: 84857785246     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/gene.2011.58     Document Type: Article

References (49)

1. Chiorazzi N, Rai K, Ferrarini M. Mechanisms of disease: chronic lymphocytic leukemia. New Eng J Med 2005; 352: 804-815.
2. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger R et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916.
3. Bullrich F, Fujii H, Calin G, Mabuchi H, Negrini M, Pekarsky Y et al. Characterization of the 13q14 tumor suppressor locus in CLL: identification of ALT1, an alternative splice variant of the LEU2 gene. Cancer Res 2001; 61: 6640-6648.
4. Liu Y, Corcoran M, Rasool O, Ivanova G, Ibbotson R, Grandér D et al. Cloning of two candidate tumor suppressor genes within a 10kb region on chromosome 13q14, frequently deleted in chronic lymphocytic leukemia. Oncogene 1997; 15: 2463-2473.
5. Lerner M, Harada M, Loven J, Castro J, Davis Z, Oscier D et al. DLEU2, frequently deleted in malignancy, functions as a critical host gene of the cell cycle inhibitory microRNAs miR-15a and miR-16-1. Exp Cell Res 2009; 315: 2941-2952.
6. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
7. Kim VN. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol 2005; 6: 376-385.
8. Newman MA, Hammond SM. Emerging paradigms of regulated microRNA processing. Genes Dev 2010; 24: 1086-1092.
9. Calin GA, Garzon R, Cimmino A, Fabbri M, Croce CM. MicroRNAs and leukemias: how strong is the connection? Leuk Res 2006; 30: 653-655.
10. Navarro F, Lieberman J. Small RNAs guide hematopoietic cell differentiation and function. J Immunol 2010; 184: 5939-5947.
11. Sevignani C, Calin GA, Siracusa LD, Croce CM. Mammalian microRNAs: a small world for fine-tuning gene expression. Mamm Genome 2006; 17: 189-202.
12. Zhao H, Wang D, Du W, Gu D, Yang R. MicroRNA and leukemia: tiny molecule, great function. Crit Rev Oncol Hematol 2010; 74: 149-155.
13. Fabbri M, Garzon R, Andreeff M, Kantarjian HM, Garcia-Manero G, Calin GA. MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications. Leukemia 2008; 22: 1095-1105.
14. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004; 101: 2999-3004.
15. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002; 99: 15524-15529.
16. Nicoloso MS, Kipps TJ, Croce CM, Calin GA. MicroRNAs in the pathogeny of chronic lymphocytic leukaemia. Br J Haematol 2007; 139: 709-716.
17. Theofilopoulos AN. Genetics of systemic autoimmunity. J Autoimmunity 1996; 9: 207-210.
18. Phillips JA, Mehta K, Fernandez C, Raveche ES. The NZB mouse as a model for chronic lymphocytic leukemia. Cancer Res 1992; 52: 437-443.
19. Scaglione BJ, Salerno E, Balan M, Coffman F, Landgraf P, Abbasi F et al. Murine models of chronic lymphocytic leukaemia: role of microRNA-16 in the New Zealand Black mouse model. Br J Haematol 2007; 139: 645-657.
20. Foster MH. Relevance of systemic lupus erythematosus nephritis animal models to human disease. Semin Nephrol 1999; 19: 12-24.
21. Dang AM, Phillips JA, Lin T, Raveche ES. Altered CD45 expression in malignant B-1 cells. Cell Immunol 1996; 169: 196-207.
22. Raveche E, Fernandes H, Ong H, Peng B. Regulatory role of T cells in a murine model of lymphoproliferative disease. Cell Immunol 1998; 187: 67-75.
23. Raveche ES, Salerno E, Scaglione BJ, Manohar V, Abbasi F, Lin YC et al. Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice. Blood 2007; 109: 5079-5086.
24. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005; 353: 1793-1801.
25. Salerno E, Scaglione BJ, Coffman FD, Brown BD, Baccarini A, Fernandes H et al. Correcting miR-15a/16 genetic defect in New Zealand Black mouse model of CLL enhances drug sensitivity. Mol Cancer Ther 2009; 8: 2684-2692.
26. Young AJ, Hay JB. Rapid turnover of the recirculating lymphocyte pool in vivo. Int Immunol 1995; 7: 1607-1615.
27. Caligaris-Cappio F, Ghia P. The normal counterpart to the chronic lymphocytic leukemia B cell. Best Pract Res Clin Haematol 2007; 20: 385-397.
28. Lanasa MC, Allgood SD, Volkheimer AD, Gockerman JP, Whitesides JF, Goodman BK et al. Single-cell analysis reveals oligoclonality among 'low-count' monoclonal B-cell lymphocytosis. Leukemia 2010; 24: 133-140.
29. Lin TT, Letsolo BT, Jones RE, Rowson J, Pratt G, Hewamana S et al. Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisis. Blood 2010; 116: 1899-1907.
30. Salerno E, Yuan Y, Scaglione BJ, Marti G, Jankovic A, Mazzella F et al. The New Zealand Black mouse as a model for the development and progression of chronic lymphocytic leukemia. Cytometry B Clin Cytom 2010; 78(Suppl 1): S98-S109.
31. Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. CMAJ 2005; 172: 367-379.
32. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004; 64: 3753-3756.
33. Calin GA, Cimmino A, Fabbri M, Ferracin M, Wojcik SE, Shimizu M et al. MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci USA 2008; 105: 5166-5171.
34. Trang P, Medina PP, Wiggins JF, Ruffino L, Kelnar K, Omotola M et al. Regression of murine lung tumors by the let-7 microRNA. Oncogene 2010; 29: 1580-1587.
35. Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, Hwang HW et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009; 137: 1005-1017.
36. Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 2008; 14: 1271-1277.
37. Takeshita F, Patrawala L, Osaki M, Takahashi R-U, Yamamoto Y, Kosaka N et al. Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther 2010; 18: 181-187.
38. Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D et al. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res 2010; 70: 5923-5930.
39. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-267.
40. VandenDriessche T, Thorrez L, Naldini L, Follenzi A, Moons L, Berneman Z et al. Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo. Blood 2002; 100: 813-822.
41. Vargas Jr J, Gusella GL, Najfeld V, Klotman ME, Cara A. Novel integrase-defective lentiviral episomal vectors for gene transfer. Hum Gene Ther 2004; 15: 361-372.
42. Fabbri M. miRNAs as molecular biomarkers of cancer. Expert Rev Mol Diagn 2010; 10: 435-444.
43. Klein U, Lia M, Crespo M, Siegel R, Shen Q, Mo T et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 2010; 17: 28-40.
44. Pegtel DM, Cosmopoulos K, Thorley-Lawson DA, van Eijndhoven MA, Hopmans ES, Lindenberg JL et al. Functional delivery of viral miRNAs via exosomes. Proc Natl Acad Sci USA 2010; 107: 6328-6333.
45. Simpson RJ, Jensen SS, Lim JW. Proteomic profiling of exosomes: current perspectives. Proteomics 2008; 8: 4083-4099.
46. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007; 9: 654-659.
47. Mittelbrunn M, Gutierrez-Vazquez C, Villarroya-Beltri C, González S, Sánchez-Cabo F, González MÁ et al. Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells. Nat Commun 2011; 2: 282.
48. Thery C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. Nat Rev Immunol 2009; 9: 581-593.
49. Ghosh AK, Secreto CR, Knox TR, Ding W, Mukhopadhyay D, Kay NE. Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression. Blood 2010; 115: 1755-1764.